Last updated on September 2018

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia


Brief description of study

The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.

Clinical Study Identifier: NCT02964936

Contact Investigators or Research Sites near you

Start Over

Astellas Pharma Inc.

Site JP00007
Aichi, Japan

Astellas Pharma Inc.

Site JP00018
Aichi, Japan

Astellas Pharma Inc.

Site JP00028
Aichi, Japan